The Board of Directors Approved 2022 Q2
Consolidated Financial Statements
Date of events
2022/08/11
To which item it meets
paragraph 31
Statement
1.Date of the board of directors submitted or approved:2022/08/11
2.Date of the audit committee approved:2022/08/11
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2022/1/1~2022/6/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):1,229,469
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):711,971
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):(883,550)
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):(815,560)
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):(815,560)
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):(815,560)
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):(2.93)
11.Total assets end of the period (thousand NTD):7,343,613
12.Total liabilities end of the period
(thousand NTD):1,728,991
13.Equity attributable to owners of parent end of the
period (thousand NTD):5,614,622
14.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
PharmaEssentia Corporation published this content on 11 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 August 2022 10:23:04 UTC.
PharmaEssentia Corp is a Taiwan-based company mainly engaged in the research, development, production and sale of new drugs. The Company is engaged in the research and development of new drugs, which are used for treatment of hematology, such as meloproliferative neoplasms (MPN), neutropenia, anemia; infectious disease, such as hepatitis C and hepatitis B; dermatology, such as psoriasis, and neurology, such as multiple sclerosis, among others. The Companyâs products include KX01, P1101, Polycythemia Vera (PV), PEG-GCSF, PEG-EPO and others. The Company distributes its products within domestic market and to overseas markets.